Results 71 to 80 of about 4,101 (234)

Gugatan Vietnam Kepada Indonesia Terkait Safeguards Produk Canai Lantaian Dari Besi Atau Baja Bukan Paduan [PDF]

, 2017
Safeguards adalah tindakan yang diambil oleh pemerintah suatu negara untuk memulihkan suatu kerugian serius atau dan/atau ancaman kerugian serius terhadap industry dalam negeri sebagai akibat dari lonjakan impor barang sejenis atau barang yang secara ...
FX Joko Priyono, Darminto Hartono, Richard Samuel*
core  

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Commented checklist of the spiders of Bavaria (Germany) [PDF]

, 2011
The checklist contains Informations on records after 1970 in the seven Bavarian counties ("Bezirke") and in whole Bavaria before 1970. A total of 747 spider species Is known from Bavaria. 14 species (Dysdera ninnii, Gonatium ensipotens, Hilaira montigena,
Blick, Theo, Scheidler, Manfred
core  

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Kesiapan Pemberlakuan Wajib Sni Susu Bubuk Dan Sni Susu Kental Manis Di Indonesia [PDF]

, 2015
Powder Milk and condensed milk are derivative products, which are widely consume, especially by toddlers. Ministry of industry has plans to impose mandatory SNI 01-2970-2006, Powder Milk and SNI 01-2971-1998, Sweetened condensed milk in Technical ...
Ayuningtyas, U. (Utari), Setyoko, A. T. (Ajun), Tampubolon, B. D. (Biatna)   +2 more
core  

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study [PDF]

, 2023
Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings.
Alhasani, H, Allan, JN, Bannerji, R, Barr, PM, Brander, DM, Brown, JR, Burne, R, Coombs, CC, Davids, MS, Eichhorst, B, Emechebe, N, Eyre, TA, Fleury, I, Guerin, A, Hill, BT, Jiang, D, Kamalakar, R, Lamanna, N, Leslie, L, Manzoor, BS, Mato, AR, Pivneva, I, Rampotas, A, Roeker, LE, Sail, K, Schuh, A, Schuster, SJ, Shadman, M, Skarbnik, A, Tuncer, HH, Ujjani, C   +30 more
core  

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, Volume 101, Issue 5, Page 1025-1035, May 2026.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Analisis Daya Saing Ekspor Sektor Pertanian Unggulan Indonesia dan Malaysia di Pasar Asean [PDF]

, 2018
This research was conducted with the aim of analyzing the competitiveness of exports of Indonesia's leading agricultural sectors and Malaysia in the ASEAN market. The data used in this study are time series secondary data from 2012 to 2016.
, Muhammad Arif, S.E., M.Ec.Dev., Pasaribu, Isnan   +1 more
core  

Population Pharmacokinetic Modeling and Exposure‐Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Nemtabrutinib plasma concentration data from 578 patients enrolled in phase 1 and 2 clinical studies, treated with doses from 5 to ...
Chiara C. Kemal, Thijs J. Zweers, Elke H. J. Krekels, Manash S. Chatterjee   +3 more
wiley   +1 more source